P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
Saved in:
Published in | Annals of oncology Vol. 33; p. S294 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.06.2022
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0923-7534 |
---|---|
DOI: | 10.1016/j.annonc.2022.04.215 |